PURPOSE This is a multicenter, single-arm phase II trial evaluating the efficacy and safety of an immune-sensitizing strategy with temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab in patients with microsatellite-stable (MSS) and O-6-methylguanine-DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer (mCRC).PATIENTS AND METHODS Patients with pretreated mCRC were centrally prescreened for MSS status and MGMT silencing (ie, lack of MGMT expression by immunohistochemistry plus MGMT methylation by pyrosequencing). Eligible patients received two priming cycles of oral temozolomide 150 mg/sqm once daily, days 1-5, once every 4 weeks (first treatment part) followed, in absence of progression, by its combination with ipilimumab 1 mg/kg once every 8 weeks and nivolumab 480 mg once every 4 weeks (second treatment part). The primary end point was the 8-month progression-free survival (PFS) rate calculated from enrollment in patients who started the second treatment part, with >= 4 out of 27 subjects progression-free by the 8-month time point as decision rule.RESULTS Among 716 prescreened patients, 204 (29%) were molecularly eligible and 135 started the first treatment part. Among these, 102 (76%) were discontinued because of death or disease progression on temozolomide priming, whereas 33 patients (24%) who achieved disease control started the second treatment part and represented the final study population. After a median follow-up of 23.1 months (interquartile range, 14.9-24.6 months), 8-month PFS rate was 36%. Median PFS and overall survival were 7.0 and 18.4 months, respectively, and overall response rate was 45%. Grade 3-4 immune-related adverse events were skin rash (6%), colitis (3%), and hypophysitis (3%). No unexpected adverse events or treatment-related deaths were reported.CONCLUSION The MAYA study provided proof-of-concept that a sequence of temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab may induce durable clinical benefit in MSS and MGMT-silenced mCRC. (c) 2022 by American Society of Clinical Oncology

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial / Morano, Federica; Raimondi, Alessandra; Pagani, Filippo; Lonardi, Sara; Salvatore, Lisa; Cremolini, Chiara; Murgioni, Sabina; Randon, Giovanni; Palermo, Federica; Antonuzzo, Lorenzo; Pella, Nicoletta; Racca, Patrizia; Prisciandaro, Michele; Niger, Monica; Corti, Francesca; Bergamo, Francesca; Zaniboni, Alberto; Ratti, Margherita; Palazzo, Michele; Cagnazzo, Celeste; Calegari, Maria Alessandra; Marmorino, Federica; Capone, Iolanda; Conca, Elena; Busico, Adele; Brich, Silvia; Tamborini, Elena; Perrone, Federica; Di Maio, Massimo; Milione, Massimo; Di Bartolomeo, Maria; de Braud, Filippo; Pietrantonio, Filippo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 40:(2022), pp. 1562-1573. [10.1200/JCO.21.02583]

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial

Antonuzzo, Lorenzo;Di Bartolomeo, Maria;
2022

Abstract

PURPOSE This is a multicenter, single-arm phase II trial evaluating the efficacy and safety of an immune-sensitizing strategy with temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab in patients with microsatellite-stable (MSS) and O-6-methylguanine-DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer (mCRC).PATIENTS AND METHODS Patients with pretreated mCRC were centrally prescreened for MSS status and MGMT silencing (ie, lack of MGMT expression by immunohistochemistry plus MGMT methylation by pyrosequencing). Eligible patients received two priming cycles of oral temozolomide 150 mg/sqm once daily, days 1-5, once every 4 weeks (first treatment part) followed, in absence of progression, by its combination with ipilimumab 1 mg/kg once every 8 weeks and nivolumab 480 mg once every 4 weeks (second treatment part). The primary end point was the 8-month progression-free survival (PFS) rate calculated from enrollment in patients who started the second treatment part, with >= 4 out of 27 subjects progression-free by the 8-month time point as decision rule.RESULTS Among 716 prescreened patients, 204 (29%) were molecularly eligible and 135 started the first treatment part. Among these, 102 (76%) were discontinued because of death or disease progression on temozolomide priming, whereas 33 patients (24%) who achieved disease control started the second treatment part and represented the final study population. After a median follow-up of 23.1 months (interquartile range, 14.9-24.6 months), 8-month PFS rate was 36%. Median PFS and overall survival were 7.0 and 18.4 months, respectively, and overall response rate was 45%. Grade 3-4 immune-related adverse events were skin rash (6%), colitis (3%), and hypophysitis (3%). No unexpected adverse events or treatment-related deaths were reported.CONCLUSION The MAYA study provided proof-of-concept that a sequence of temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab may induce durable clinical benefit in MSS and MGMT-silenced mCRC. (c) 2022 by American Society of Clinical Oncology
2022
40
1562
1573
Morano, Federica; Raimondi, Alessandra; Pagani, Filippo; Lonardi, Sara; Salvatore, Lisa; Cremolini, Chiara; Murgioni, Sabina; Randon, Giovanni; Palermo, Federica; Antonuzzo, Lorenzo; Pella, Nicoletta; Racca, Patrizia; Prisciandaro, Michele; Niger, Monica; Corti, Francesca; Bergamo, Francesca; Zaniboni, Alberto; Ratti, Margherita; Palazzo, Michele; Cagnazzo, Celeste; Calegari, Maria Alessandra; Marmorino, Federica; Capone, Iolanda; Conca, Elena; Busico, Adele; Brich, Silvia; Tamborini, Elena; Perrone, Federica; Di Maio, Massimo; Milione, Massimo; Di Bartolomeo, Maria; de Braud, Filippo; Pietrantonio, Filippo
File in questo prodotto:
File Dimensione Formato  
jco-40-1562.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 689.97 kB
Formato Adobe PDF
689.97 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1286721
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 49
social impact